Business
Placing, Subscription and Open Offer
Placing, Subscription and Open Offer.
About this update from Cambridge Nutritional Sciences Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5377K\n Omega Diagnostics Group PLC\n 06 May 2022\n \n \n \n \n \n \n \n The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \n \n \n \n \n \n \n OMEGA DIAGNOSTICS GROUP PLC\n \n \n \n \n \n (\"Omega\" or the \"Company\" or the \"Group\")\n \n \n \n \n \n \n \n \n Placing of 50,000,000 New Ordinary Shares and Warrants\n \n \n Subscription of 2,125,000 New Ordinary Shares \n \n \n Open Offer of up to 49,860,515 New Ordinary Shares \n \n \n and\n \n \n Notice of General Meeting\n \n \n \n \n \n Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has raised gross proceeds of £2.0 million via a Placing of 50,000,000 new ordinary shares of 4.0 pence each (\"New Ordinary Shares\") and 90,000,000 warrants to subscribe for Ordinary shares (the \"Warrants\") to institutional investors at an issue price of 4.0 pence per New Ordinary Share (the \"Issue Price\"). \n \n \n \n \n \n Furthermore, the Company also announces a conditional raise of up to an additional £2.0 million by the issue of up to 49,860,515 New Ordinary Shares pursuant to an Open Offer to Qualifying Shareholders at the Issue Price (\"Open Offer\"), and a subscription by Directors for an additional 2,125,000 New Ordinary Shares (the \"Subscription\", together with the Placing and Open Offer the \"Fundraising\"). \n Subscribers to the Placing have also been issued Warrants to subscribe for one additional Ordinary Share at the Issue Price in the ratio of nine Warrants for every five Placing Shares issued to those subscribers. \n The Issue Price is the same as the closing mid-market price of 4.0 pence on 5 May 2022, being the latest practicable date prior to this announcement. \n \n \n \n \n \n The net proceeds of the Fundraising, amounting to between £1.75 million and £7.25 million, depending on the take up of the Open Offer and the number of Warrants exercised, will be used to initially fund the CD4 business...